Endocrine Practice is a premier journal dedicated to the dynamic and evolving field of endocrinology, published by Elsevier Inc.. With a significant emphasis on clinical practice, research, and advancements in the multidisciplinary domains of endocrinology, diabetes, and metabolism, this journal serves as a vital resource for researchers, healthcare professionals, and students alike. As a recognized leader in its field, it boasts an impressive impact factor and is ranked in the Q1 quartile for both Endocrinology and Medicine categories, reflecting its high-quality research contributions and relevance to contemporary clinical practice. The journal enjoys a robust reputation, achieving Scopus rankings with a placement of #57 out of 244 in Endocrinology, Diabetes and Metabolism, and #37 out of 128 in Biochemistry, Genetics and Molecular Biology. Although it is not available as open access, Endocrine Practice continues to disseminate critical findings from 2000 through to 2024, ensuring that professionals remain at the forefront of endocrine research and clinical application.

The Turkish Journal of Endocrinology and Metabolism, published by AVES, is a prominent platform dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. As an Open Access journal since 2002, it provides unrestricted access to its content, fostering a global exchange of knowledge among researchers, clinicians, and students. Operating from Turkey, this journal plays a crucial role in disseminating innovative findings related to endocrine disorders and metabolic diseases. While its current Q4 quartile rankings in both Endocrinology and Internal Medicine underscore areas for growth, they also signify the journal’s commitment to enhancing its impact within these disciplines. The journal emphasizes the development of locally relevant research while encouraging international contributions, thus bridging gaps in global health discourse. Engage with cutting-edge research that shapes clinical practices and informs public health policies by submitting your work or exploring the journal’s vast archive from 2009 to 2023.

The International Journal of Endocrinology and Metabolism is a leading peer-reviewed publication dedicated to advancing knowledge and research in the fields of endocrinology, diabetes, and metabolism. Published by BRIEFLAND in the Netherlands, this journal features original research, comprehensive reviews, and insightful clinical studies that explore the multifaceted aspects of hormonal disorders and metabolic conditions. With an impact factor that places it in the Q3 quartile category for 2023, the journal serves as a critical resource for academics and practitioners aiming to stay at the forefront of this dynamic field. Spanning from 2010 to 2024, the journal offers an enriching platform for innovative ideas and practices, fostering collaboration among scholars and healthcare professionals alike. Although not open access, the content is meticulously curated to ensure high-quality scientific discourse, positioning the International Journal of Endocrinology and Metabolism as an essential reference for those dedicated to improving health outcomes related to endocrine and metabolic disorders.

HORMONE AND METABOLIC RESEARCH, published by GEORG THIEME VERLAG KG, stands as a reputable platform in the fields of biochemistry, endocrinology, and metabolism since its establishment in 1969. This peer-reviewed journal provides critical insights and advancements in the intricate relationships between hormones and metabolic processes, catering to researchers, healthcare professionals, and students alike. With an impressive convergence of knowledge spanning over five decades, it maintains a commendable Q3 ranking in multiple categories, including Biochemistry, Clinical Biochemistry, and Endocrinology, highlighting its contribution to cutting-edge scientific discourse. Although not an open-access journal, it offers a plethora of access options for readers and institutions, ensuring that vital research reaches those who need it most. Located in Stuttgart, Germany, the journal is positioned at the forefront of influential research in hormone and metabolic studies, emphasizing its importance for ongoing investigations into health and disease.

The JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, published by Walter de Gruyter GmbH, is a reputable peer-reviewed journal dedicated to advancing the field of pediatric endocrinology and metabolism. Since its inception in 1985, this journal has become a vital resource for professionals and researchers, providing insights into the latest advancements, clinical practices, and foundational research in the care of children with endocrine disorders. With a noted Q3 ranking in Endocrinology, Diabetes and Metabolism, and a robust focus on Pediatrics, Perinatology, and Child Health, it addresses important topics such as hormonal imbalances and metabolic syndromes in young populations. Despite its non-open access status, it continues to play an essential role in bridging the knowledge gap within our understanding of children's health and disease, contributing significantly to the progress in this specialized field.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, published by the Endocrine Society, stands as a premier academic journal within the field of endocrinology, diabetes, and metabolism. With a legacy spanning from 1941 to 2024, this journal is distinguished by its significant impact factor, ranking in the Q1 category across multiple related disciplines including biochemistry, clinical biochemistry, and medicine. This esteemed journal, ISSN 0021-972X and E-ISSN 1945-7197, is backed by rigorous peer review, ensuring the publication of high-quality research that contributes to the advancement of clinical practices and scientific knowledge. With a commendable Scopus ranking, positioned in the top percentile of multiple categories, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM serves as an essential resource for researchers, professionals, and students who seek to stay informed about the latest findings and innovations in endocrine research. The journal enriches the existing body of knowledge and fosters discussion among scholars and practitioners alike, solidifying its crucial role in the ongoing discourse in endocrinology and metabolic health.

Endocrine Metabolic & Immune Disorders-Drug Targets, published by Bentham Science Publishers, is a premier journal focused on the intricate interplay between endocrinology, metabolism, and immune response, with a particular emphasis on drug targets. Established in 2006 and set to continue its influence until 2024, this journal serves as a crucial platform for researchers and professionals to communicate significant advances in understanding metabolic and immune disorders, making it an invaluable resource in the realms of Endocrinology and Immunology. With an impact factor positioned within the Q3 category for both Endocrinology, Diabetes and Metabolism, and Immunology and Allergy as of 2023, the journal stands at the crossroads of critical research and clinical application, facilitating ongoing dialogue among the scientific community. Although currently not open access, its dedication to high-quality peer-reviewed articles ensures that cutting-edge research remains accessible to those invested in enhancing therapeutic strategies. For researchers and practitioners alike, Endocrine Metabolic & Immune Disorders-Drug Targets is an essential conduit for the latest findings that can influence treatment paradigms and bolster the understanding of complex biological systems.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.